Carvedilol: A review of its use in chronic heart failure

Drugs

Volumn 63, Issue 16, 2003, Pages 1697-1741

  Keating, Gillian M ^a   Jarvis, Blair ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BUCINDOLOL; CARVEDILOL; CIMETIDINE; CYCLOSPORIN; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FLUOXETINE; GLIBENCLAMIDE; HYDROCHLOROTHIAZIDE; INOTROPIC AGENT; METOPROLOL; RIFAMPICIN; TORASEMIDE; WARFARIN;

ALPHA ADRENERGIC RECEPTOR BLOCKING; ANTIOXIDANT ACTIVITY; ATRIOVENTRICULAR BLOCK; BETA ADRENERGIC RECEPTOR BLOCKING; BRADYCARDIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG HALF LIFE; DRUG METABOLISM; DRUG TOLERABILITY; DRUG USE; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART VENTRICLE REMODELING; HUMAN; HYPOTENSION; LIVER DISEASE; METABOLIC ACIDOSIS; NAUSEA; OBSTRUCTIVE AIRWAY DISEASE; PHEOCHROMOCYTOMA; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; VERTIGO;

ADRENERGIC BETA-ANTAGONISTS; CARBAZOLES; CHRONIC DISEASE; DRUG ADMINISTRATION SCHEDULE; HEART FAILURE, CONGESTIVE; HUMANS; MODELS, BIOLOGICAL; PROPANOLAMINES; TREATMENT OUTCOME;

EID: 0042233484     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200363160-00006     Document Type: Review

References (178)

1. Feuerstein G, Yue T-L, Ma X, et al. Novel mechanisms in the treatment of heart failure: inhibition of oxygen radicals and apoptosis by carvedilol. Prog Cardiovasc Dis 1998; 41 (1 Suppl. 1): 17-24
2. Ruffolo Jr RR, Feuerstein GZ. Neurohormonal activation, oxygen free radicals, and apoptosis in the pathogenesis of congestive heart failure. J Cardiovasc Pharmacol 1998; 32 Suppl. 1: S22-30
3. Packer M, Coats AJS, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001 May 31; 344 (22): 1651-8
4. Bristow M. Mechanism of action of beta-blocking agents in heart failure. Am J Cardiol 1997 Dec 4; 80 (11A): 26L-40L
5. Metra M, Nodari S, D'Aloia A, et al. Effects of neurohormonal antagonism on symptoms and quality-of-life in heart failure. Eur Heart J 1998 Feb; 19 Suppl. B: B25-35
6. McTavish D, Campoli-Richards D, Sorkin EM. Carvedilol: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 1993; 45 (2): 232-58
7. Dunn CJ, Lea AP, Wagstaff AJ. Carvedilol: a reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders. Drugs 1997; 54 (1): 161-85
8. Al-Hesayen A, Azevedo ER, Mak S, et al. Randomized comparison of the effects of metoprolol or carvedilol on cardiac and sympathetic activity in chronic heart failure [abstract no. 3761]. Circulation 2000 Oct 31; 102 (18 Suppl. 2): 779
9. Angermann CE, Costard-Jaeckle A, Deng MC, et al. Is carvedilol safe and efficacious in severe heart failure patients accepted for heart transplantation [abstract no. 295]? J Heart Lung Transplant 2001 Feb; 20 (2): 250-1
10. Dalle Mule J, Cleland JGF, Pennel DJ, et al. Effect of carvedilol to correct interventricular dyssynchrony in patients with chronic heart failure due to ischemic left ventricular systolic dysfunction: results of the CHRISTMAS study [abstract and poster]. 52nd Annual Scientific Session of the American College of Cardiology; 2003 Mar 30-Apr 2; Chicago (IL)
11. Bergstrom A, Andersson B, Edner M, et al. Carvedilol improves diastolic function in patients with diastolic heart failure [abstract no. 3388]. Circulation 2001 Oct 23; 104 (17 Suppl. 2): 718
12. Brunvand H, Frøyland L, Hexeberg E, et al. Carvedilol reduces infarct size and improves post-ischaemic functional recovery by protecting against both ischaemic and reperfusion injury [abstract no. 1929]. Eur Heart J 1995 Aug; 16 Suppl.: 338
13. Berdeaux A, Lindenbaum A, Giudicelli J-F, et al. Lack of antioxidant effect of six months carvedilol treatment in patients with chronic heart failure [abstract no. 3042]. Circulation 2000 Oct 31; 102 (18 Suppl. 2): 627
14. Abraham WT, Tsvetkova T, Lowes BD, et al. Carvedilol improves renal hemodynamics in patients with chronic heart failure [abstract no. 1987]. Circulation 1998 Oct 27; 98 Suppl. 1: 378-9
15. Refsgaard J, Andreasen F, Goetzsche O. Improvement of endothelial dysfunction in patients with congestive heart failure during treatment with carvedilol [abstract no. 1993]. Eur Heart J 1999 Aug; 20 Suppl.: 375
16. Remme WJ, Riegger G, Hildebrandt P, et al. Do patients necessarily have to start with an angiotensin converting enzyme inhibitor in the treatment of heart failure? Results of the CARMEN (Carvedilol ACE inhibitor remodelling mild CHF Evaluation) study [abstract and poster]. 52nd Annual Scientific Session of the American College of Cardiology; 2003 Mar 29-Apr 2: Chicago (IL)
17. Remme WJ, Soler-Soler J, Ryden L, et al. Replacement of angiotensin converting enzyme inhibition by carvedilol results in long-term reversed left ventricular remodelling in mild heart failure and is well tolerated: results of the CARMEN (Carvedilol ACE-inhibitor Remodeling in Mild Heart Failure Evaluation) study [abstract and poster]. 52nd Annual Scientific Session of the American College of Cardiology; 2003 Mar 30-Apr 2; Chicago (IL)
18. Doughty RN, Whalley GA, Walsh H, et al. Effects of carvedilol on left ventricular remodelling in patients following acute myocardial infaction: the CAPRICORN echo substudy [abstract no. 2447]. Circulation 2001 Oct; 104 (17 Suppl.): 517
19. Goldhammer E, Shnitzer S, Kagan T, et al. The anti-oxidant effect of carvedilol correlates with the clinical outcome in congestive heart failure and predicts it [abstract no. 194]. Cardiovasc Drugs Ther 2000; 14 (2): 202
20. Ruffolo Jr RR, Feuerstein GZ. Carvedilol: preclinical profile and mechanisms of action in preventing the progression of congestive heart failure. Eur Heart J 1998 Feb; 19 Suppl. B: B19-24
21. Morgan T. Clinical pharmacokinetics and pharmacodynamics of carvedilol. Clin Pharmacokinet 1994; 26 (5): 335-46
22. Yoshikawa T, Port JD, Asano K, et al. Cardiac adrenergic receptor effects of carvedilol. Eur Heart J 1996; 17 Suppl. B: 8-16
23. Metra M, Nodari S, Dei Cas L. β-Blockade in heart failure: selective versus nonselective agents. Am J Cardiovasc Drugs 2001; 1 (1): 3-14
24. Willette RN, Aiyar N, Yue TL, et al. In vitro and in vivo characterization of intrinsic sympathomimetic activity in normal and heart failure rats. J Pharmacol Exp Ther 1999; 289 (1): 48-53
25. Kubo T, Azevedo ER, Newton GE, et al. Lack of evidence for peripheral alpha1-adrenoceptor blockade during long-term treatment of heart failure with carvedilol. J Am Coll Cardiol 2001 Nov 1; 38 (5): 1463-9
26. Gilbert EM, Abraham WT, Olsen S, et al. Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation 1996 Dec 1; 94 (11): 2817-25
27. Bristow MR, Gilbert EM, Abraham WT, et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 1996; 94 (11): 2807-16
28. Cohn JN, Fowler MB, Bristow MR, et al. Safety and efficacy of carvedilol in severe heart failure. U.S. Carvedilol Heart Failure Study Group. J Card Fail 1997; 3: 173-9
29. Colucci WS, Packer M, Bristow MR, et al. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. Circulation 1996; 94: 2800-6
30. Packer M, Colucci WS, Sackner-Bernstein JD, et al. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure: the PRECISE trial. Circulation 1996 Dec 1; 94 (11): 2793-9
31. Doughty RN, Whalley GA, Gamble G, et al. Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease. J Am Coll Cardiol 1997; 29 (5): 1060-6
32. Krum H, Sackner-Bernstein JD, Goldsmith RL, et al. Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure. Circulation 1995 Sep 15; 92 (6): 1499-506
33. Olsen SL, Gilbert EM, Renlund DG, et al. Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study. J Am Coll Cardiol 1995 May; 25 (6): 1225-31
34. Guazzi M. Agostoni P, Matturri M, et al. Pulmonary function, cardiac function, and exercise capacity in a follow-up of patients with congestive heart failure treated with carvedilol. Am Heart J 1999; 138: 460-7
35. Cice G, Ferrara L, Di Bennedetto A, et al. Dilated cardiomyopathy in dialysis patients - beneficial effects of carvedilol: a double-blind, placebo-controlled trial. J Am Coll Cardiol 2001; 37 (2): 407-11
36. Metra M, Giubbini R, Nodari S, et al. Differential effects of β-blockers in patients with heart failure: a prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol. Circulation 2000 Aug 1; 102: 546-51
37. Packer M, Antonopolous GV, Berlin JA, et al. Comparative effects of carvedilol and metoprolol on left ventricular ejection fraction in heart failure: resuls of a meta-analysis. Am Heart J 2001 Jun; 141 (6): 899-907
38. Australia/New Zealand Heart Failure Research Collaborative Group. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Lancet 1997; 349: 375-80
39. Palazzuoli A, Bruni F, Puccetti L, et al. Effects of carvedilol on left ventricular remodeling and systolic function in elderly patients with heart failure. Eur J Heart Fail 2002 Dec; 4 (6): 765-70
40. Piccirillo G, Quaglione R, Nocco M, et al. Effects of long-term beta-blocker (metoprolol or carvedilol) therapy on QT variability in subjects with chronic heart failure secondary to ischemic cardiomyopathy. Am J Cardiol 2002 Nov 15; 90 (10): 1113-7
41. Ridha M, Mäkikallio TH, Lopera G, et al. Effects of carvedilol on heart rate dynamics in patients with congestive heart failure. Ann Noninvasive Electrocardiol 2002 Apr; 7 (2): 133-8
42. Bøttcher M, Refsgaard J, Gøtzsche O, et al. Effect of carvedilol on microcirculatory and glucose metabolic regulation in patients with congestive heart failure secondary to ischemic cardiomyopathy. Am J Cardiol 2002 Jun 15; 89 (12): 1388-93
43. Åsbrink S, Zickert A, Bratt J, et al. No effect of carvedilol on nitric oxide generation in phagocytes but modulation of production of superoxide ions. Biochem Pharmacol 2000; 59: 1007-13
44. Lysko PG, Webb CL, Gu J-L, et al. A comparison of carvedilol and metoprolol antioxidant activities in vitro. J Cardiovasc Pharmacol 2000; 36 (2): 277-81
45. Oettl K, Greilberger J, Zangger K, et al. Radical-scavenging and iron-chelating properties of carvedilol, an antihypertensive drug with antioxidative activity. Biochem Pharmacol 2001; 62 (2): 241-8
46. Santos DJSL, Moreno AJM. Inhibition of heart mitochondrial lipid peroxidation by non-toxic concentrations of carvedilol and its analog BM-910228. Biochem Pharmacol 2001; 61: 155-64
47. Yue T-L, Cheng H-Y, Lysko PG, et al. Carvedilol, a new vasodilator and beta adrenoceptor antagonist, is an antioxidant and free radical scavenger. J Pharmacol Exp Ther 1992; 263 (1): 92-8
48. Yue T-L, Liu T, Feuerstein G. Carvedilol, a new vasodilator and β-adrenoceptor antagonist, inhibits oxygen-radical-mediated lipid peroxidation in swine ventricular membranes. Pharmacol Commun 1992; 1 (1): 27-35
49. Yue TL, McKenna PJ, Gu JL, et al. Carvedilol, a new antihypertensive agent, prevents lipid peroxidation and oxidative injury to endothelial cells. Hypertension 1993 Dec; 22 (6): 922-8
50. Yue T-L, McKenna PJ, Lysko PG, et al. Carvedilol, a new antihypertensive, prevents oxidation of human low density lipoprotein by macrophages and copper. Atherosclerosis 1992; 97: 209-16
51. Yue T-L, McKenna PJ, Ruffolo Jr RR, et al. Carvedilol, a new β-adrenoceptor antagonist and vasodilator antihypertensive drug, inhibits superoxide release from human neutrophils. Eur J Pharmacol 1992; 214: 277-80
52. Yue T-L, Wang X, Gu J-L, et al. Carvedilol, a new vasodilating beta-adrenoceptor blocker, inhibits oxidation of low-density lipoproteins by vascular smooth muscle cells and prevents leukocyte adhesion to smooth muscle cells. J Pharmacol Exp Ther 1995; 273 (3): 1442-9
53. Yue T-L, Wang X, Gu J-L. Carvedilol prevents low-density lipoprotein (LDL)-enhanced monocyte adhesion to endothelial cells by inhibition of LDL oxidation. Eur J Pharmacol 1995; 294: 585-91
54. Dandona P, Karne R, Ghanim H, et al. Carvedilol inhibits reactive oxygen species generation by leukocytes and oxidative damage to amino acids. Circulation 2000 Jan 18; 101: 122-4
55. Maggi E, Marchesi E, Covini D, et al. Protective effects of carvedilol, a vasodilating β-adrenoceptor blocker, against in vivo low density lipoprotein oxidation in essential hypertension. J Cardiovasc Pharmacol 1996; 27 (4): 532-8
56. Giugliano D, Acampora R, Marfella R, et al. Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension: a randomized, control trial. Ann Intern Med 1997 Jun 15; 126 (12): 955-9
57. Arumanayagam M, Chan S, Tong S, et al. Antioxidant properties of carvedilol and metoprolol in heart failure: a double-blind randomized controlled trial. J Cardiovasc Pharmacol 2001; 37: 48-54
58. Kukin ML, Kalman J, Charney RH, et al. Prospective, randomized comparison of effect of long-term treatment with metoprolol or carvedilol on symptoms, exercise, ejection fraction, and oxidative stress in heart failure. Circulation 1999 May 25; 99: 2645-51
59. Nakamura K, Kusano K, Nakamura Y, et al. Carvedilol decreases elevated oxidative stress in human failing myocardium. Circulation 2002 Jun 18; 105 (24): 2867-71
60. Rössig L, Haendeler J, Mallat Z, et al. Congestive heart failure induces endothelial cell apoptosis: protective role of carvedilol. J Am Coll Cardiol 2000 Dec; 36 (7): 2081-9
61. Romeo F, Li D, Shi M, et al. Carvedilol prevents epinephrine-induced apoptosis in human coronary artery endothelial cells: modulation of Fas/Fas ligand and caspase-3 pathway. Cardiovasc Res 2000; 45: 788-94
62. Yue T-L, Ma X-L, Wang XK, et al. Possible involvement of stress-activated protein kinase signaling pathway and fas receptor expression in prevention of ischemia/reperfusion-induced cardiomyocyte apoptosis by carvedilol. Circ Res 1998; 82: 166-74
63. Sung C-P, Arleth AJ, Ohlstein EH. Carvedilol inhibits vascular smooth muscle cell proliferation. J Cardiovasc Pharmacol 1993; 21 (2): 221-7
64. Patel MK, Chan P, Betteridge LJ. Inhibition of human vascular smooth muscle cell proliferation by the novel multiple-action antihypertensive agent carvedilol. J Cardiovasc Pharmacol 1995; 25 (4): 652-7
65. Ohlstein EH, Douglas SA, Sung CP, et al. Carvedilol, a cardiovascular drug, prevents vascular smooth muscle cell proliferation, migration, and neointimal formation following vascular injury. Proc Natl Acad Sci U S A 1993 Jul; 90: 6189-93
66. 1-β-blockade in congestive heart failure. Scand J Clin Lab Invest 2002; 62 (2): 97-104
67. de Boer RA, Siebelink H-MJ, Tio RA, et al. Carvedilol increases plasma vascular endothelial growth factor (VEGF) in patients with chronic heart failure. Eur J Heart Fail 2001; 3: 331-3
68. Ohtsuka T, Hamada M, Saeki H, et al. Comparison of effects of carvedilol versus metoprolol on cytokine levels in patients with idiopathic dilated cardiomyopathy. Am J Cardiol 2002 Apr 15; 89 (8): 996-9
69. Stoschitzky K, Koshucharova G, Zweiker R, et al. Differing beta-blocking effects of carvedilol and metoprolol. Eur J Heart Fail 2001; 3: 343-9
70. Packer M. β-Blockade in heart failure: basic concepts and clinical results. Am J Hypertens 1998 Jan; 11 (1): 23S-37S
71. Flesch M, Ettelbrück S, Rosenkranz S, et al. Differential effects of carvedilol and metoprolol on isoprenaline-induced changes in β-adrenoceptor density and systolic function in rat cardiac myocytes. Cardiovasc Res 2001; 49: 371-80
72. Herman RB, Jesudason PJ, Mustafa AM, et al. Differential effects of carvedilol and atenolol on plasma noradrenaline during exercise in humans. Br J Clin Pharmacol 2003 Feb; 55 (2): 134-8
73. Cleland JGF, Pennell DJ, Ray SG, et al. Myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with heart failure (CHRISTMAS): randomised controlled trial. Lancet 2003 Jul 5; 362: 14-21
74. Di Lenarda A, Sabbadini G, Salvatore L, et al. Long-term effects of carvedilol in idiopathic dilated cardiomyopathy with persistent left ventricular dysfunction despite chronic metoprolol. J Am Coll Cardiol 1999; 33 (7): 1926-34
75. Metra M, Nardi M, Giubbini R. Effects of short- and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 1994; 24 (7): 1678-87
76. Sanderson JE, Chan SKW, Yip G, et al. Beta-blockade in heart failure: a comparison of carvedilol with metoprolol. J Am Coll Cardiol 1999 Nov 1; 34 (5): 1522-8
77. Poole-Wilson PA, Swedberg K, Cleland JGF, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003 Jul 5; 362: 7-13
78. Capomolla S, Pinna GD, Febo O, et al. Echo-Doppler mitral flow monitoring: an operative tool to evaluate day-to-day tolerance to and effectiveness of beta-adrenergic blocking agent therapy in patients with chronic heart failure. J Am Coll Cardiol 2001 Nov 15; 38 (6): 1675-84
79. Khattar RS, Senior R, Soman P, et al. Regression of left ventricular remodeling in chronic heart failure: comparative and combined effects of captopril and carvedilol. Am Heart J 2001 Oct; 142 (4): 704-13
80. Senior R, Basu S, Kinsey C, et al. Carvedilol prevents remodeling in patients with left ventricular dysfunction after acute myocardial infarction. Am Heart J 1999 Apr; 137 (4): 646-52
81. Remme WJ. The Carvedilol and ACE-Inhibitor Remodelling Mild Heart Failure Evaluation trial (CARMEN): rationale and design. CARMEN Steering Committee. Cardiovasc Drugs Ther 2001; 15: 69-77
82. Basu S, Senior R, Raval U, et al. Beneficial effects of intravenous and oral carvedilol treatment in acute myocardial infarction: a placebo-controlled, randomized trial. Circulation 1997; 96: 183-91
83. Karle CA, Kreye VAW, Thomas D, et al. Antiarrythmic drug carvedilol inhibits HERG potassium channels. Cardiovasc Res 2001; 49: 361-70
84. Feuerstein GZ, Yue T-L, Cheng H-Y, et al. Myocardial protection by the novel vasodilating beta-blocker, carvedilol: potential relevance of anti-oxidant activity. J Hypertens 1993 Jun; 11 Suppl. 4: S41-8
85. Bril A, Slivjak M, DiMartino MJ, et al. Cardioprotective effects of carvedilol, a novel β-adrenoceptor antagonist with vasodilating properties, in anaesthetised minipigs: comparison with propranolol. Cardiovasc Res 1992; 26: 518-25
86. Smith III EF, Griswold DE, Hillegass LM, et al. Cardioprotective effects of the vasodilator/beta-adrenoceptor blocker, carvedilol, in two models of myocardial infarction in the rat. Pharmacology 1992 Jun; 44 (6): 297-305
87. Ruffolo Jr RR, Bril A, Feuerstein GZ. Cardioprotective potential of carvedilol. Cardiology 1993; 82 Suppl. 3: 24-8
88. Feuerstein GZ, Ruffolo Jr RR. Comparison of the ability of two vasodilating β-blockers, carvedilol and celiprolol, to reduce infarct size in a pig model of acute myocardial infarction. Pharmacol Commun 1994; 5 (1): 57-63
89. Bril A, Tomasi V, Laville M-P. Antiarrhythmic effects of carvedilol in rat isolated heart subjected to regional ischemia and reperfusion. Pharmacol Commun 1995; 5 (4): 291-300
90. Höher M, Friedrich M, Sommer T, et al. Effects of carvedilol on left ventricular function and arrhythmias during repeated short-time myocardial ischemia in experimental pigs. Z Kardiol 1989; 78 Suppl. 3: 7-15
91. Noguchi N, Nishino K, Niki E. Antioxidant action of the anti-hypertensive drug carvedilol, against lipid peroxidation. Biochem Pharmacol 2000; 59 (9): 1069-76
92. Tadolini B, Franconi F. Carvedilol inhibition of lipid peroxidation: a new antioxidative mechanism. Free Radic Res 1998; 29: 377-87
93. Keith M, Geranmayegan A, Sole MJ, et al. Increased oxidative stress in patients with congestive heart failure. J Am Coll Cardiol 1998 May; 31 (6): 1352-6
94. Douglas SA, Vickery-Clark LM, Louden C, et al. Acute pretreatment with carvedilol is sufficient for inhibition of neointima formation following rat carotid artery balloon angioplasty. Pharmacol Commun 1994; 5 (1): 65-72
95. Fassbinder W, Quarder O, Waltz A. Treatment with carvedilol is associated with a significant reduction in microalbuminuria: a multicentre randomised study. Int J Clin Pract 1999; 53 (7): 519-22
96. Marchi F, Ciriello G. Efficacy of carvedilol in mild to moderate essential hypertension and effects on microalbuminuria: a multicenter, randomized, open-label, controlled study versus atenolol. Adv Ther 1995; 12 (4): 212-21
97. Refsgaard J, Thomsen C, Andreasen F, et al. Carvedilol does not alter the insulin sensitivity in patients with congestive heart failure. Eur J Heart Fail 2002 Aug; 4 (4): 445-53
98. von Möllendorff E, Reiff K, Neugebauer G. Pharmacokinetics and bioavailability of carvedilol, a vasodilating beta- blocker. Eur J Clin Pharmacol 1987; 33: 511-3
99. Louis WJ, McNeil JJ, Workman BS, et al. A pharmacokinetic study of carvedilol (BM 14.190) in elderly subjects: preliminary report. J Cardiovasc Pharmacol 1987; 10 Suppl. 11: S89-93
100. GlaxoSmithKline. COREG® (carvedilol) tablets: prescribing information [online]. Available from URL: http://www.gsk.com [Accessed 2003 May 9]
101. Carlson W, Oberg K. Clinical pharmacology of carvedilol. J Cardiovasc Pharmacol Ther 1999; 4 (4): 205-18
102. Oldham HG, Clarke SE. In vitro identification of the human cytochrome P450 enzymes involved in the metabolism of R(+)- and S(-)-carvedilol. Drug Metab Dispos 1997; 25 (8): 970-7
103. Neugebauer G, Akpan W, von Möllendorff E, et al. Pharmacokinetics and disposition of carvedilol in humans. J Cardiovasc Pharmacol 1987; 10 Suppl. 11: S85-8
104. Fujimaki M, Murakoshi Y, Hakusui H. Assay and disposition of carvedilol enantiomers in humans and monkeys: evidence of stereoselective presystemic metabolism. J Pharm Sci 1990 Jul; 79 (7): 568-72
105. Bristow MR, Abraham WT, Gilbert EM, et al. Relationships between carvedilol stereoisomer plasma concentrations and β-receptor occupancies in subjects with chronic heart failure in the Multicenter Oral Carvedilol Heart Failure Assessment (MOCHA) trial [abstract no. 802]. Eur Heart J 1996 Aug; 17 Suppl.: 135
106. Zhou H-H, Wood AJJ. Stereoselective disposition of carvedilol is determined by CYP2D6. Clin Pharmacol Ther 1995 May; 57 (5): 518-24
107. Tenero D, Ilson B, Boyle D, et al. Dose-proportional stereoselective kinetics of carvedilol in patients with CHF [abstract no. PIII-54]. Clin Pharmacol Ther 1996; 59 (2): 201
108. Morgan TO, Anderson A, Cripps J, et al. The use of carvedilol in elderly hypertensive patients. Eur J Clin Pharmacol 1990; 38: S129-33
109. Morgan T, Anderson A, Cripps J, et al. Pharmacokinetics of carvedilol in older and younger patients. J Hum Hypertens 1990; 4: 709-15
110. Gehr TWB, Tenero DM, Boyle DA, et al. The pharmacokinetics of carvedilol and its metabolites after single and multiple dose oral administration in patients with hypertension and renal insufficiency. Eur J Clin Pharmacol 1999; 55: 269-77
111. Neugebaner G, Gabor M, Reiff K. Pharmacokinetics and bioavailability of carvedilol in patients with liver cirrhosis. Drugs 1988; 36 Suppl. 6: 148-54
112. Graft DW, Williamson KM, Pieper JA, et al. Effects of fluoxetine on carvedilol pharmacokinetics, CYP2D6 activity, and autonomic balance in heart failure patients. J Clin Pharmacol 2001; 41: 97-106
113. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996 May 23; 334 (21): 1349-55
114. Macfarlane PW, Murray GD, McGowan J, et al. Analysis of 24 hour ambulatory ECGs from the CHRISTMAS study [abstract no. 3026]. Circulation 2002 Nov 5; 106 (19 Suppl.): 613
115. Cice G, Tagliamonte E, Ferrara L, et al. Efficacy of carvedilol on complex ventricular arrhythmias in dilated cardiomyopathy: double-blind, randomized, placebo-controlled study. Eur Heart J 2000 Aug; 21 (15): 1259-64
116. Pamboukian SV, Aminbakhsh A, Thompson CR, et al. Carvedilol improves functional class in patients with severe left ventricular dysfunction referred for heart transplantation. Clin Transplant 1999; 13: 426-31
117. Kumar A, Choudhary G, Antonio C, et al. Carvedilol titration in patients with congestive heart failure receiving inotropic therapy. Am Heart J 2001 Sep; 142 (3): 512-5
118. Macdonald PS, Keogh AM, Aboyoun CL, et al. Tolerability and efficacy of carvedilol in patients with New York Heart Association class IV heart failure. J Am Coll Cardiol 1999 Mar 15; 33 (4): 924-31
119. Rector TS, Cohn JN. Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Am Heart J 1992 Oct; 124 (4): 1017-25
120. The CAPRICORN Investigators. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001 May 5; 357: 1385-90
121. Bristow MR. β-Adrenergic receptor blockade in chronic heart failure. Circulation 2000; 101: 558-69
122. Schmidt BM, Janson CP, Wehling M. Assuming the worst may not be bad at all: carvedilol in heart failure treatment. Eur J Clin Pharmacol 1998; 54: 281-5
123. Pfeffer MA, Stevenson LW. β-Adrenergic blockers and survival in heart failure. N Engl J Med 1996 May 23; 334 (21): 1396-7
124. Yancy CW, Fowler MB, Wilson S, et al. Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure. N Engl J Med 2001 May 3; 344 (18): 1358-65
125. Joglar JA, Acusta AP, Shusterman NH, et al. Effect of carvedilol on survival and hemodynamics in patients with atrial fibrillation and left ventricular dysfunction: retrospective analysis of the US Carvedilol Heart Failure Trials Program. Am Heart J 2001 Sep; 142 (3): 498-501
126. Cice G, Ferrara L, D'Andrea A, et al. Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial. J Am Coll Cardiol 2003 May 7; 41 (9): 1438-44
127. Doughty RN, Rodgers A, Sharpe N, et al. Effects of beta-blocker therapy on mortality in patients with heart failure: a systematic overview of randomized controlled trials. Eur Heart J 1997; 18 (4): 560-5
128. Lechat P, Packer M, Chalon S, et al. Clinical effects of β-adrenergic blockade in chronic heart failure: a meta-analysis of double-blind, placebo-controlled, randomized trials. Circulation 1998 Sep 22; 98: 1184-91
129. Packer M, Fowler MB, Roecker EB, et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study. Circulation 2002 Oct 22; 106 (17): 2194-9
130. Lechat P, Bouzamondo A, Sanchez P, et al. Relationships between baseline risk and treatment effect of beta-blockers in heart failure [abstract no. P1650]. Eur Heart J 2000; 21 Suppl.: 297
131. The Beta-Blocker Evaluation of Survival Trial Investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 2001 May 31; 344 (22): 1659-67
132. Krum H, Roecker EB, Mohacsi P, et al. Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS study. JAMA 2003 Feb 12; 289 (6): 712-8
133. Anker SD, Coats AJS, Roecker EB, et al. Does carvedilol prevent and reverse cardiac cachexia in patients with severe heart failure? Results of the COPERNICUS study [abstract no. 2077]. Eur Heart J 2002; 23 Suppl.: 394
134. Carson P, Fowler MB, Mohacsi P, et al. Effect of carvedilol in Black patients with severe chronic heart failure: results of the COPERNICUS study [abstract no. 3550]. Circulation 2001 Oct; 104 (17 Suppl.): 754
135. Mohacsi P, Fowler MB, Krum H, et al. Should physicians avoid the use of beta-blockers in patients with heart failure who have diabetes? Results of the COPERNICUS study [abstract no. 3551]. Circulation 2001 Oct 23; 104 (17 Suppl. 2): 754
136. Tendera MP, Coats AJ, Fowler MB, et al. Effect of gender on the outcome of patients with severe heart failure treated with carvedilol: results of the COPERNICUS study [abstract no. 858-5]. J Am Coll Cardiol 2002 Mar 6; 39 (5 Suppl. A): 185A
137. Rouleau JL, Krum H, Katus HA, et al. Efficacy and safety of carvedilol in patients with low systolic blood pressure in the COPERNICUS study [abstract no. 2082]. Eur Heart J 2002; 23 Suppl.: 396
138. Katus HA, Tendera M, Mohacsi P, et al. Effect of carvedilol on major clinical events in patients with severe heart failure and an extremely depressed ejection fraction [abstract no. 2704]. Eur Heart J 2002; 23 Suppl.: 514
139. Krum H, Mohacsi P, Katus HA, et al. Is additional neurohormonal antagonism useful in patients with severe chronic heart failure already receiving a combination of neurohormonal antagonists? Results of the COPERNICUS study [abstract]. J Am Coll Cardiol 2002; 39 Suppl. A: 177A-8A
140. Dargie HJ. Design and methodology of the CAPRICORN trial - a randomised double blind placebo controlled study of the impact of carvedilol on morbidity and mortality in patients with left ventricular dysfunction after myocardial infarction. CAPRICORN Steering Committee. Eur J Heart Fail 2000; 2: 325-32
141. Sharpe N, Sendon JLL, Colucci WS, et al. Effects of carvedilol on clinical outcome in patients with left ventricular dysfunction after myocardial infarction: the CAPRICORN study [abstract no. 1642]. Circulation 2001 Oct 23; 104 (17 Suppl. 2): 343
142. McMurray JJ, Dargie HJ, Ford I, et al. Carvedilol reduces supraventricular and ventricular arrhythmias after myocardial infarction: evidence from the CAPRICORN study [abstract no. 3303]. Circulation 2001 Oct; 104 (17 Suppl.): 700
143. Sackner-Bernstein J, Ford I, Robertson M, et al. Effect of carvedilol on major cardiovascular events in post-infarction patients treated with angiotensin converting enzyme inhibitors: further analysis of the CAPRICORN trial [abstract and poster]. 52nd Annual Scientific Session of the American College of Cardiology; 2003 Mar 30-Apr 2; Chicago (IL)
144. Delea TE, Vera-Llonch M, Richner RE, et al. Cost effectiveness of carvedilol for heart failure. Am J Cardiol 1999; 83: 890-6
145. Levy AR, Briggs AH, Demers C, et al. Cost-effectiveness of β-blocker therapy with metoprolol or with carvedilol for treatment of heart failure in Canada. Am Heart J 2001 Sep; 142 (3): 537-43
146. Gregory D, Udelson JE, Konstam MA. Economic impact of beta blockade in heart failure. Am J Med 2001 May 7; 110 Suppl.: 74S-80S
147. Fowler MB, Vera-Llonch M, Oster G, et al. Influence of carvedilol on hospitalizations in heart failure: incidence, resource utilization and costs. J Am Coll Cardiol 2001 May; 37 (6): 1692-9
148. Vera-Llonch M, Menzin J, Richner RE, et al. Cost-effectiveness results from the US Carvedilol Heart Failure Trials Program. Ann Pharmacother 2001; 35: 846-51
149. Stewart S, McMurray JJV, Hebborn A, et al. Carvedilol reduces the costs of medical care in severe heart failure: an economic analysis of the COPERNICUS study applied to the United Kingdom [abstract no. 807]. Eur Heart J 2002; 23 Suppl.: 136
150. White TJ, Chang EY, Leslie RS, et al. Economic outcomes of patients receiving carvedilol compared to those receiving no beta-blocker therapy for the treatment of congestive heart failure in a managed care organization [abstract no. PCV29]. Value Health 2001; 4 (2): 106
151. Najib MM, Goldberg Arnold RJ, Kaniecki DJ, et al. Medical resource use and costs of congestive heart failure after carvedilol use. Heart Dis 2002 Mar; 4 (2): 70-7
152. Luzier AB, Antell LA, Chang L-L, et al. Reimbursement claims analysis of outcomes with carvedilol and metoprolol. Ann Pharmacother 2002 Mar; 36: 386-91
153. Krum H, Coats AJ, Fowler MB, et al. Safety and tolerability of carvedilol in patients with severe chronic heart failure: results of the COPERNICUS study [abstract no. 3383]. Circulation 2001 Oct; 104 (17 Suppl.): 717
154. Krum H, Ninio D, MacDonald P. Baseline predictors of tolerability to carvedilol in patients with chronic heart failure. Heart 2000; 84: 615-9
155. Matsuda N, Endo Y, Uchida Y, et al. Plasma brain natriuretic peptide
156. Roche. Carvedilol: summary of product characteristics [online]. Available from URL: http://www.rocheuk.com [Accessed 2003 Mar 11]
157. Hunt SA, Baker DW, Chin MH, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary: a report of the American College of Cardiology/American Heart Assocation Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). Circulation 2001 Dec 11; 104: 2996-3007
158. Remme WJ, Swedberg K. Guidelines for the diagnosis and treatment of chronic heart failure: Task Force for the Diagnosis and Treatment of Chronic Heart Failure. European Society of Cardiology. Eur Heart J 2001 Sep; 22 (17): 1527-60
159. Agostoni P, Guazzi M, Bussotti M, et al. Carvedilol reduces the inappropriate increase of ventilation during exercise in heart failure patients. Chest 2002 Dec; 122 (6): 2062-7
160. Otterstad J, Ford I. The effect of carvedilol in patients with impaired left ventricular systolic function following an acute myocardial infarction. How do the treatment effects on total mortality and recurrent myocardial infarction in CAPRICORN compare with previous beta-blocker trials? Eur J Heart Fail 2002 Aug; 4 (4): 501
161. Wexler DJ, Chen J, Smith GL, et al. Predictors of costs of caring for elderly patients discharged with heart failure. Am Heart J 2001; 142 (2): 350-7
162. Packer M. Current role of beta-adrenergic blockers in the management of chronic heart failure. Am J Med 2001 May; 110 (7A): 81S-94S
163. Cleland JGF, Cohen-Solal A, Cosin Aguilar J, et al. Management of heart failure in primary care (the IMPROVEMENT of Heart Failure Programme): an international survey. Lancet 2002 Nov 23; 360: 1631-9
164. Pinski SL. Continuing progress in the treatment of severe congestive heart failure. JAMA 2003 Feb 12; 289 (6): 754-6
165. Gheorghiade M, Gattis WA, Lukas MA, et al. Rationale and design of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy for Heart Failure (IMPACT-HF) study. Am Heart J 2003 Feb; 145 (2 Suppl.): S60-1
166. Klein L, O'Connor CM, Gattis WA, et al. Pharmacologic therapy for patients with chronic heart failure and reduced systolic function: review of trials and practical considerations. Am J Cardiol 2003 May 8; 91 (9A): 18-40
167. Andreka P, Aiyar N, Olson LC, et al. Bucindolol displays intrinsic sympathomimetic activity in human myocardium. Circulation 2002 May 21; 105 (20): 2429-34
168. Hjalmarson A, Goldstein S, Fagerberg B, et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: The Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). JAMA 2000 Mar 8; 283 (10): 1295-302
169. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet 1999; 353: 2001-7
170. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999 Jan 2; 353: 9-13
171. Krum H. β-Blockers in heart failure: the new wave of clinical trials. Drugs 1999 Aug; 58 (2): 203-10
172. Bristow MR. What type of β-blocker should be used to treat chronic heart failure? Circulation 2000; 102: 484-6
173. Wollert KC, Drexler H. Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Trial: carvedilol as the sun and center of the β-blocker world? Circulation 2002 Oct 22; 106 (17): 2164-6
174. Dargie HJ. β blockers in heart failure. Lancet 2003 Jul 5; 362: 2-3
175. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999 Sep 2; 341 (10): 709-17
176. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 1995 May 10; 273 (18): 1450-6
177. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991 Aug 1; 325 (5): 293-302
178. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med 1987 Jun 4; 316 (23): 1429-35